These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29253458)

  • 21. Survival impact of the Australian National Bowel Cancer Screening Programme.
    Ananda S; Wong H; Faragher I; Jones IT; Steele M; Kosmider S; Desai J; Tie J; Field K; Wong R; Tran B; Bae S; Gibbs P
    Intern Med J; 2016 Feb; 46(2):166-71. PubMed ID: 26418334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of a mass media campaign on participation rates in a National Bowel Cancer Screening Program: a field experiment.
    Durkin SJ; Broun K; Spittal MJ; Wakefield MA
    BMJ Open; 2019 Jan; 9(1):e024267. PubMed ID: 30813110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High participation rates are not necessary for cost-effective colorectal cancer screening.
    Howard K; Salkeld G; Irwig L; Adelstein BA
    J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
    Todorov K; Wilson C; Sharplin G; Corsini N
    Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising the expansion of the National Bowel Cancer Screening Program.
    Cenin DR; St John DJ; Ledger MJ; Slevin T; Lansdorp-Vogelaar I
    Med J Aust; 2014 Oct; 201(8):456-61. PubMed ID: 25332032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
    Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
    Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing bowel cancer screening participation: integrating population-wide, primary care and more targeted approaches.
    Lofti-Jam KL; O'Reilly CL; Feng CS; Wakefield MA; Durkin S; Broun KH
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endoscopist-directed propofol administration versus anesthesiologist assistance for colorectal cancer screening: a cost-effectiveness analysis.
    Hassan C; Rex DK; Cooper GS; Benamouzig R
    Endoscopy; 2012 May; 44(5):456-64. PubMed ID: 22531982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bowel cancer screening--a role for general practice.
    Foreman L
    Aust Fam Physician; 2009 Apr; 38(4):200-3. PubMed ID: 19350068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
    Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
    Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
    Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
    Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colorectal cancer screening in rural and remote areas: analysis of the National Bowel Cancer Screening Program data for South Australia.
    Martini A; Javanparast S; Ward PR; Baratiny G; Gill T; Cole S; Tsourtos G; Aylward P; Jiwa M; Misan G; Wilson C; Young GP
    Rural Remote Health; 2011; 11(2):1648. PubMed ID: 21585228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.